Cerebrolysin (Porcine Brain-Derived Peptide Mixture) Guide

Cerebrolysin – Compound Identity
Full name	Cerebrolysin
Nature	Heterogeneous mixture of low-molecular-weight neuropeptides (~25%) and free amino acids (~75%) derived from enzymatic breakdown of purified porcine brain proteins
Manufacturer	EVER Neuro Pharma GmbH, Unterach, Austria
Route	Intravenous infusion or intramuscular injection
Clinical dose range	10-30 mL/day IV over multi-week courses (per published trial protocols)
Approvals	Approved in 50+ countries including Austria, Germany, Russia, China, South Korea. Not approved in US, UK, Australia, Canada.
Clinical trial volume	200+ clinical trials involving upward of 15,000 patients (per published literature)
Key contraindication	Epilepsy/seizure disorders, severe renal impairment, porcine allergy
Category	Neuropeptide mixture (cognitive and neuropeptide cluster)

What Is Cerebrolysin?

Cerebrolysin is not a single peptide. It is a standardised mixture produced by controlled enzymatic hydrolysis of purified porcine (pig) brain proteins. The resulting preparation contains a complex array of low-molecular-weight peptide fragments and free amino acids. A 2023 analytical study by Yang and colleagues in the Journal of Chromatography B used NanoLC-MS mass spectrometry to characterise the active constituents and identified a mixture of short-chain peptides rather than any single defined molecular entity.

This heterogeneity is clinically relevant. Cerebrolysin has no single compound identifier, no defined active pharmaceutical ingredient in the conventional sense, and cannot be replicated by any other manufacturer. It exists as a proprietary product of EVER Neuro Pharma GmbH, based in Unterach, Austria. The preparation has been manufactured and used in clinical settings since the early 1970s.

The bottom line: Cerebrolysin occupies a unique position in neuropharmacology. It is neither a single-molecule drug nor a traditional biologic. It is a defined-process extract – the product is what comes out of a specific, standardised manufacturing process applied to porcine brain tissue.

How Is Cerebrolysin Proposed to Work?

The core hypothesis is that Cerebrolysin’s peptide constituents mimic the effects of endogenous neurotrophic factors – specifically brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF). Because the peptide fragments are small enough to cross the blood-brain barrier where full-sized growth factors cannot, the preparation is proposed to deliver neurotrophic-factor-like activity directly to the central nervous system.

ELISA analysis has confirmed that Cerebrolysin contains CNTF, GDNF, IGF-1, IGF-2, and other factors structurally similar to endogenous neurotrophic factors. The proposed mechanisms include promotion of neurogenesis, synaptic plasticity, angiogenesis, anti-inflammatory signalling, inhibition of calpain-mediated neurodegeneration, and modulation of amyloid-beta and tau pathways relevant to Alzheimer’s disease.

A 2023 narrative review by Rejdak, Sienkiewicz-Jarosz, Bienkowski, and Alvarez in Medicinal Research Reviews summarised these proposed mechanisms. It is worth noting that several authors of that review declared ties to EVER Neuro Pharma. An independent 2024 in-vitro study published in Cureus confirmed BDNF upregulation by Cerebrolysin in neural cell cultures, providing mechanistic support from outside the manufacturer’s network, though in-vitro findings cannot be directly extrapolated to clinical outcomes.

Cerebrolysin activates the PI3K/Akt signalling pathway – the same pathway activated by BDNF – and the SHH (Sonic Hedgehog) pathway, which facilitates neuroplasticity and neurogenesis. Recent studies have shown effects on cerebral vascular inflammation and blood-brain barrier integrity through increased tight junction expression.

The bottom line: the proposed mechanism is plausible and supported by preclinical data. The core limitation is that Cerebrolysin’s heterogeneous composition makes it impossible to attribute observed clinical effects to specific molecular components.

What Does the Clinical Evidence Show?

Cerebrolysin has the most extensive clinical trial programme of any compound in this cluster, with more than 200 published trials. The clinical evidence spans three main therapeutic areas: acute ischaemic stroke, Alzheimer’s disease, and traumatic brain injury. The critical question is not whether trials exist – they do, in volume – but what independent systematic review has concluded about their quality.

Acute ischaemic stroke

This is the most extensively studied indication. The landmark trials include CASTA (Heiss 2012), CARS (Muresanu 2016), and CEREHETIS (Khasanova and Kalinin 2023). A 2025 systematic review and meta-analysis by Patel and colleagues in Cureus pooled 14 randomised controlled trials with 2,884 patients. The pooled analysis found that Cerebrolysin significantly improved neurological recovery as measured by NIHSS score change (mean difference +1.39 points, 95% CI 0.53-2.25, p=0.020). Functional independence (mRS 0-2) showed a non-significant trend in favour of Cerebrolysin. No significant differences were observed in serious adverse events, mortality, or haemorrhagic transformation.

The CARS trial (Muresanu 2016) was a randomised, placebo-controlled, double-blind, multicentre study. The multivariate effect size on global status, assessed using 12 different outcome scales, indicated a small-to-medium superiority for Cerebrolysin (Mann-Whitney estimator 0.62, 95% CI 0.58-0.65, p<0.0001). Premature discontinuation was below 5%.

The CASTA study (Heiss 2012) was a double-blind, placebo-controlled trial in Asian stroke patients. The overall primary endpoint did not reach statistical significance, but a pre-specified subgroup analysis of severely affected patients (NIHSS above 12) showed significant decreases in mortality and disability.

Alzheimer’s disease and vascular dementia

Several randomised, double-blind, placebo-controlled trials have tested Cerebrolysin in Alzheimer’s disease, including studies by Ruether (2001), Panisset (2002), Alvarez (2006), and Alvarez (2011). A meta-analysis of six such trials found Cerebrolysin significantly more effective than placebo for cognitive function at four weeks, with effect sizes comparable to approved cholinesterase inhibitors.

For vascular dementia, the Cochrane review by Cui and colleagues (2019, updating Chen 2013) pooled six RCTs with 597 participants and found “some evidence that Cerebrolysin has a small positive effect on global clinical state, cognitive function, and functional ability.” However, the reviewers flagged short follow-up periods (six months or less), small sample sizes, and risk of bias. They rated one trial as good quality, four as fair, and one as poor.

An EVER Pharma-sponsored Phase 4 study comparing Cerebrolysin to donepezil in mild-to-moderate Alzheimer’s dementia has been registered (NCT01822951), reflecting the manufacturer’s continued pursuit of comparative efficacy data.

Traumatic brain injury

The CAPTAIN trial series evaluated Cerebrolysin in moderate-to-severe TBI across multiple centres. A prospective meta-analysis by Muresanu and Vester (2020) summarised the programme. Contemporary clinical evidence encompasses 10 published studies in over 1,900 TBI patients treated with Cerebrolysin. Results suggest potential benefit in early post-TBI recovery, but a separate systematic review noted that conclusions were weakened by imprecision and methodological flaws. The original CAPTAIN trial (NCT01606111) was terminated early due to poor patient recruitment.

Indication	Trial volume	Cochrane assessment	Evidence tier
Acute ischaemic stroke	14 RCTs, 2,884 patients	Low to very low certainty (Ziganshina 2023)	Moderate quantity, low quality
Alzheimer’s disease	6+ RCTs	Very low certainty (Cochrane)	Moderate quantity, low quality
Vascular dementia	6 RCTs, 597 patients	Low quality, possible small effect (Cui 2019)	Limited quantity, low quality
Traumatic brain injury	10 studies, 1,900+ patients	Imprecision and methodological flaws noted	Moderate quantity, uncertain quality

The ESCAS Aphasia Trial: Cerebrolysin’s Newest Evidence

The most recent addition to the Cerebrolysin clinical evidence base is the ESCAS trial (Efficacy and Safety of Cerebrolysin in the Treatment of Aphasia After Acute Ischemic Stroke), published in Stroke in February 2025 by Homberg, Jianu, Stan, Muresanu, and colleagues. This is a notable study for two reasons: it tests a novel indication (nonfluent aphasia rather than motor recovery), and it is the first randomised trial to evaluate Cerebrolysin specifically as an adjunct to speech and language therapy.

ESCAS was a prospective, randomised, double-blind, placebo-controlled pilot study conducted at two Romanian stroke centres between June 2020 and October 2022. Participants had left middle cerebral artery territory ischaemic stroke with nonfluent aphasia and were enrolled three to five days post-stroke. The intervention group received Cerebrolysin combined with structured speech therapy; the control group received placebo saline with the same speech therapy protocol. Concomitant use of Cerebrolysin for motor recovery was not permitted, isolating the language-specific signal.

The study is classified as a Phase 4 post-marketing surveillance study, conducted after Cerebrolysin’s existing drug approvals in multiple European countries. The full dataset has been made publicly available at Harvard Dataverse, which is unusual for Cerebrolysin research and represents a step toward the transparency that critics have called for.

Why the Anglosphere Says No: The Regulatory Geography Problem

Cerebrolysin presents a regulatory puzzle that is worth examining directly, because the geographic split in its approval status reveals something important about how evidence is evaluated differently across regulatory systems. The compound is approved as a prescription drug in Austria, Germany, Russia, China, South Korea, and more than 45 other countries. It is not approved in the United States, United Kingdom, Australia, or Canada. The Anglosphere regulators have not simply declined to approve Cerebrolysin – they have never received an application to evaluate.

Three structural factors explain this gap. First, Cerebrolysin is a biological extract with no single defined active ingredient. The FDA, MHRA, and TGA all operate regulatory frameworks built around defined molecules. A proprietary brain extract does not fit neatly into any existing approval pathway – it is neither a small molecule, a biologic with a defined sequence, nor a traditional compound eligible for 503A compounding. A US approval would require a full New Drug Application with de novo clinical trials meeting FDA standards, which EVER Pharma has never initiated.

Second, the evidence quality bar differs. Many of the countries where Cerebrolysin is approved have regulatory traditions that accept industry-sponsored RCTs with smaller sample sizes and shorter follow-up as sufficient evidence. The FDA and MHRA demand larger, independently replicated trials with pre-registered primary endpoints – the kind of evidence the Cochrane reviewers have repeatedly found lacking.

Third, there is no commercial incentive. EVER Pharma operates profitably in its existing markets. The cost of running the Phase III programme needed for FDA approval – likely requiring thousands of patients across multiple US centres – would run into hundreds of millions of dollars, with no guarantee of success. For a company already selling in 50+ countries, the risk-reward calculation has never favoured pursuing the Anglosphere markets.

The bottom line: Cerebrolysin’s absence from the US, UK, and Australian markets is not a regulatory rejection. It is the product of a structural mismatch between the compound’s nature, the manufacturer’s commercial strategy, and the evidence standards of Anglosphere regulators. The distinction matters because “not approved” and “evaluated and rejected” are very different regulatory statements.

The Research Integrity Problem

Any assessment of Cerebrolysin’s evidence base must address the research integrity concerns that emerged in 2024-2025 around several key preclinical researchers. Multiple Cerebrolysin papers have been flagged, investigated, or retracted due to concerns about image manipulation and data integrity.

As of early 2026, eight out of 21 Cerebrolysin papers by one senior NIH-affiliated researcher have been placed under investigation. Separately, 25 out of 39 Cerebrolysin papers and book chapters by a Uppsala University research group have been flagged on PubPeer, with five already retracted or removed – including three chapters retracted along with an entire book the authors had written and edited. A former general manager at EVER Pharma appeared as a co-author on multiple affected papers.

The retracted studies are preclinical, not clinical. BMC Neuroscience retracted at least two Cerebrolysin papers in 2025 after identifying overlapping image panels across panels that represented different experimental conditions, a finding inconsistent with independent data collection.

The Cochrane Verdict

The Cochrane systematic review of Cerebrolysin for acute ischaemic stroke has been published in three editions (2010, 2020, 2023), each reaching the same sceptical conclusion. The most recent edition by Ziganshina and colleagues is worth examining in detail because it represents the highest-quality independent evidence assessment available.

The 2023 Cochrane review pooled seven RCTs with 1,773 participants. Key findings: no evidence of beneficial effect on all-cause death (RR 0.96, 95% CI 0.65 to 1.41, 6 trials, 1,689 participants, moderate-certainty evidence). A statistically significant increase in non-fatal serious adverse events in the Cerebrolysin group (RR 2.39, 95% CI 1.10 to 5.23, 3 trials, 1,335 participants), with the signal more pronounced at the 30 mL for 10 days dose (RR 2.87, 95% CI 1.24 to 6.69).

The Cochrane authors rated overall certainty of evidence for benefit as low to very low. A separate Cochrane review of Cerebrolysin for vascular dementia (Cui 2019, updating Chen 2013) found no new eligible studies since 2013 and maintained its assessment that evidence quality was insufficient to support routine use.

The bottom line: the Cochrane position – three editions, same conclusion – is that the available evidence cannot confidently distinguish between a real treatment effect and the combination of methodological limitations and publication bias from a single interested sponsor. This does not mean Cerebrolysin is ineffective. It means the data, as currently constituted, cannot prove it works.

Safety Profile

Across its extensive published trial programme, Cerebrolysin’s reported adverse event profile has generally been comparable to placebo. The most commonly reported adverse events in trials include headache, dizziness, nausea, and injection-site reactions. Across published RCTs, premature discontinuation rates have typically been below 5%.

There are three important safety considerations. First, the 2023 Cochrane review identified a statistically significant increase in non-fatal serious adverse events, which introduces uncertainty about the safety profile at standard clinical doses. Second, Cerebrolysin is contraindicated in patients with epilepsy or seizure disorders because its neurotrophic and neuroexcitatory properties may lower the seizure threshold. Third, its porcine origin means it is contraindicated for anyone with a known allergy to pork or porcine-derived products.

Additional contraindications in the approved prescribing information (where available) include severe renal impairment and allergic diathesis.

The bottom line: Cerebrolysin is generally well tolerated in published trials, but the Cochrane serious adverse event signal at the 30 mL dose level cannot be dismissed, and the compound’s neurotrophic mechanism means seizure risk is a genuine concern for susceptible patients.

Regulatory Status

Jurisdiction	Status
United States (FDA)	Not approved for any indication. No New Drug Application has been filed. Does not fit the standard compounding framework because it is a proprietary porcine brain extract with no single defined active pharmaceutical ingredient.
United Kingdom (MHRA)	Not licensed. No marketing authorisation.
Australia (TGA)	Not approved. Not listed on the ARTG.
Canada	Not approved.
Austria, Germany	Approved as a prescription drug for stroke and neurological conditions.
Russia	Approved as a prescription drug for stroke, TBI, and dementia.
China, South Korea	Approved as a prescription drug.
WADA	Not individually listed. As a porcine-derived neuropeptide mixture approved in some countries, its status depends on the specific regulatory context of the athlete’s jurisdiction.

Cerebrolysin’s regulatory position is unlike any other compound in this cluster. It is an approved prescription drug in more than 50 countries, used in routine clinical practice across Europe, Asia, and Latin America. Yet the Anglosphere regulators – FDA, MHRA, TGA, Health Canada – have never approved it. This split reflects different evidence standards and regulatory traditions rather than a simple pass/fail judgment on the compound itself.

Unlike compounds such as Semax and DSIP, Cerebrolysin is not part of the FDA’s peptide compounding framework and has no Category 1 or Category 2 placement. Its proprietary, biologically-derived nature places it outside the 503A bulk drug substance pathway entirely. Any US regulatory path would require a full New Drug Application, which EVER Pharma has not pursued.

For the broader regulatory picture across key peptide markets, see our guides covering the US, the UK and Australia.

The Sponsor Concentration Problem

Cerebrolysin’s clinical trial programme is overwhelmingly industry-sponsored. EVER Neuro Pharma has funded or co-funded the majority of published RCTs, and company employees or consultants appear as authors on many of the key publications. The 2023 Cochrane review explicitly noted this concentration of sponsorship as a source of potential publication bias.

This does not invalidate the trial results – industry-sponsored trials can produce reliable data. But it does mean that the absence of large, independently funded trials is a meaningful gap. Unlike the Russian peptide compounds in this cluster, which have programme-level evidence concentration in a national research network, Cerebrolysin’s evidence concentration is centred on a single commercial manufacturer with a direct financial interest in positive outcomes.

A 2023 secondary cost-effectiveness analysis of the CARS data was industry-affiliated and reported a favourable cost-effectiveness ratio. The Cochrane authors noted that such analyses do not resolve the primary evidence quality questions they have raised.

The bottom line: Cerebrolysin has more clinical trial data than most compounds in the peptide space. The problem is not quantity but quality. When independent reviewers apply rigorous systematic review methodology, the evidence shrinks to “low to very low certainty” – a pattern that has not changed across three Cochrane editions spanning 13 years.

How Cerebrolysin Fits Within the Neuropeptide Landscape

Cerebrolysin is fundamentally different from every other compound in this cluster. It is not a synthetic peptide with a defined sequence. It is not a product of the Russian peptide engineering programme. It is a proprietary biological extract with no structural relationship to the ACTH-derived or tuftsin-derived lineages.

Its regulatory pathway is also distinct. Where Semax and DSIP are navigating the FDA’s 503A compounding framework through the PCAC hearing process, Cerebrolysin would require a full NDA – a fundamentally different and far more expensive regulatory route. This structural difference helps explain why Cerebrolysin has been available for clinical use in 50+ countries for decades without ever reaching the US, UK, or Australian markets.

For a broader overview of all compounds in this cluster and how they compare, see the nootropic and neuropeptide compounds hub.

Sourcing and Quality

Cerebrolysin is a registered pharmaceutical product in countries where it is approved and is obtained through legitimate medical channels – pharmacy dispensing on a prescription. In countries where it is not approved (including the US, UK, and Australia), there is no authorised supply chain. Individuals who source Cerebrolysin outside its approved markets should verify that the product is genuine EVER Pharma stock and has been stored and shipped according to cold-chain requirements, as biological products degrade without proper handling.

Because Cerebrolysin is a proprietary extract rather than a defined chemical compound, it cannot be independently synthesised by third-party research chemical suppliers. Any product labelled “cerebrolysin” that does not come from EVER Pharma’s manufacturing facility in Austria is not the compound studied in the published clinical trials. For general guidance on evaluating compound quality documentation, see our guide to reading a certificate of analysis.